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Abstract
Chronic cannabis use has been shown to block long-term depression of GABA-glutamate synapses in the striatum, which is
likely to reduce the extent to which endogenous cannabinoids modulate GABA- and glutamate-related neuronal activity.
The current study aimed at investigating the effect of this process on striatal dopamine levels by studying the spontaneous
eye blink rate (EBR), a clinical marker of dopamine level in the striatum. 25 adult regular cannabis users and 25 non-user
controls matched for age, gender, race, and IQ were compared. Results show a significant reduction in EBR in chronic users
as compared to non-users, suggesting an indirect detrimental effect of chronic cannabis use on striatal dopaminergic
functioning. Additionally, EBR correlated negatively with years of cannabis exposure, monthly peak cannabis consumption,
and lifetime cannabis consumption, pointing to a relationship between the degree of impairment of striatal dopaminergic
transmission and cannabis consumption history.
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Introduction
Cannabis (Cannabis sativa) is the most widely used illicit drug in
Europe and the US. Its recreational use dates back to over 2000
years B.C. The active compounds in cannabis are called exogenous
cannabinoids, with delta-9-tetrahydrocannabinol (THC) and can-
nabidiol (CBD) being responsible for most of the drug’s psychoac-
tive effects [1]. Current research indicates that THC, as a
cannabinoid CB1 receptor agonist, indirectly affects dopaminergic
functioning. Stimulation of the cannabinoid receptor type 1 (CB1)
results in the release of dopamine (DA) [2]—a neurotransmitter
involved in the control of goal-directed behavior, reward learning,
reinforcement, and addiction [3]. However, CB1 receptors are not
present at dopaminergic neurons. Instead, they are located in
Gamma Amino Butyric Acid (GABA) and glutamatergic terminals
which, in turn, influence DA/D1 and DA/D2 neurons by
controlling DA inhibition. In other words, CB1 receptors contribute
to the release of DA by inhibiting DA inhibitors.
Interestingly, the highest concentrations of CB1 receptors in the
brain can be observed at the same areas where dopaminergic
neurons are present [3]. Crucial regions in this regard seem to be
the basal ganglia and, more specifically, the striatum, in which
endogenous cannabinoids modulate the firing of DA neurons. This
occurs through postsynaptic interactions between cannabinoids
and DA at the level of G-protein/adenylyl cyclase signal
transduction [4]. As a consequence, it makes sense to assume that
any effect of THC on DA transmission is the product of an
indirect process. This is different from the impact of other often
abused drugs, like amphetamine or cocaine, which seems to act
directly on DA neurons (for a discussion, see [5]).
Hitherto, two studies using Positron Emission Tomography have
looked into the acute effect of THC on striatal DA transmission—
with however inconsistent results: one study reported a THC-
induced increase in striatal DA level [6] while another found no
effect [7]. Things are even less clear with regard to chronic effects of
long-term exposure to THC, on which no data are available. This is
particularly unfortunate in view of Kuepper’s et al. [8] suggestion
that repeated THC administration may create a dopaminergic
imbalance in the brain by increasing striatal DA levels but lowering
DA levels in prefrontal cortex. As a possible consequence of this
imbalance, chronic THC exposure has been assumed to induce
psychotic symptoms in users [8]. However, a problem with this
assumption is that it is not based on any evidence regarding chronic
effects of THC on striatal DA transmission but on only one finding
regarding the acute effects [6]. Therefore, it is not clear whether
THC actually induces long-term dopaminergic imbalances.
To address this issue, the present study aimed at investigating
the effect of long-term exposure to cannabis on striatal DA
transmission. In the case of chronic effects, it is difficult to
differentiate between the specific psychoactive plant components
which caused the potential impairments. Consequently, we use the
more generic term ‘‘cannabis’’ in the present study, even though
the available data suggest that the observed effects are mainly due
to the impact of THC. For one, from the two main studied
psychoactive compounds of cannabis, only THC acts as a CB1
receptor agonist, while CBD functions as an antagonist. For
another, CBD is suspected to reduce the psychotic effects of THC,
which would suggest a role of CBD in diminishing the potential
DA-impairing effects of THC [9]. Nevertheless, for the sake of
precision, no reference to specific cannabinoids is made.
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eye blink rates (EBR), a well-established clinical marker of striatal
DA production [10–12]. Numerous observations have helped to
validate EBR as a measure of striatal DA functioning. For
instance, deviant levels of EBR have been reported from patients
suffering from DA-related impairments: While EBR is elevated in
schizophrenic patients, who exhibit increased striatal DA trans-
mission [13], EBR is lowered in Parkinson’s patients, who have a
reduced amount of nigrostriatal dopaminergic neurons [14]. In
addition, EBRs vary as a function of the DRD4/7 genotype,
which is associated with the modulation of DA level in the striatum
[15]. Moreover, nonhuman primate research has shown that
direct DA agonists and antagonists increase and decrease EBRs,
respectively [16].
Exact predictions of how chronic cannabis use might affect the
striatal DA level—and the associated EBR—can be derived from
animal research. Hoffman et al. [17] showed that, in rats, chronic
treatment with a CB1 receptor agonist results in a reduced
sensitivity of CB1 receptors located at glutamatergic and
GABAergic terminals. Moreover, chronic application of THC
completely blocks long-term depression (LTD) of GABA-gluta-
mate synapses in the striatum. Normally, the regulatory role of
LTD is to inhibit the activity of GABA and glutamate neurons
and, thus, to block their control over DA neurons, which again
allows for DA transmission. Consequently, blocking LTD should
reduce the extent to which endogenous cannabinoids modulate
GABA and glutamate neuron activity. Moreover, the LTD-DA
relationship appears to be bidirectional: striatal DA neurons are
capable of synthesizing endogenous cannabinoids, which induce
LTD and interact with DA as a supplementary inhibitory feedback
mechanism [3,4]. However, in the case of chronic cannabis use,
the decreased sensitivity of CB1 receptors implies that the
likelihood of endogenous cannabinoids evoking LTD is lowered.
As a result of this bidirectional process, chronic application of
exogenous cannabinoids present in cannabis could be expected to
lead to decreased DA transmission due to long-term, maladaptive
inhibition by GABA and glutamate [17]. If so, we would expect a
decrease of spontaneous EBR in chronic cannabis users as
compared to non-users.
Results
EBR per minute was significantly lower in chronic cannabis
users (M=10.24; SD=5.861) than in the non-user controls
(M=17.52; SD=9.019), t(48)=3.384, p,.01. The same effect was
obtained in an ANOVA with group (chronic cannabis users vs.
non-user controls) as independent variable and IQ and cigarette
use as covariates: while the group effect was again significant, F(1,
46)=5.477, p,.05, the covariate effects were not.
To test whether the EBR in the chronic cannabis users was
related to their consumption history and habits, Spearman’s Rho
correlation coefficients were calculated between EBR/minute and
the years of cannabis exposure, age of onset, monthly regular,
monthly peak and lifetime cannabis consumption. EBR correlated
negatively with years of exposure, r(25)=2.42, p,.05 (see
Figure 1), monthly peak consumption, r(25)=2.43, p,.05 (see
Figure 2), and lifetime consumption, r(25)=2.40, p,.05 (see
Figure 3), while no significant correlations were found for age of
onset, r(25)=2.04, p= n.s., and monthly regular consumption,
r(25) =2.25, p= n.s.
Discussion
The results of the study show a significant reduction of
spontaneous EBR in chronic cannabis users, as compared to
non-user controls. This can be interpreted as an indication of a
dopaminergic hypoactive state in the striatum [10–12]. Addition-
ally, a moderate negative correlation between EBR and years of
cannabis exposure suggests that the degree of impairment of DA
transmission is, to a certain extent, proportional to the period of
cannabis use. Conversely, the lack of a correlation between EBR
and the age of onset of cannabis consumption suggests that starting
to use marijuana at an earlier age does not contribute to the level
of dopaminergic hypoactivity. However, such a claim should be
treated with caution due to the fact that adolescent cannabis use
has been linked to specific cognitive impairments, like less efficient
discrimination between relevant and irrelevant stimuli [18]. In any
case, it can be assumed that the striatal dopaminergic hypoactive
state of chronic cannabis users is the result of blocking the
supplementary inhibitory mechanism of LTD. The impairment of
GABA and glutamate neuron activity combined with the down-
regulation of CB1 receptors seem to be plausible explanations for
the observed decreased EBR in chronic users [3,4,17].
In the case of the modest negative correlation between EBR and
monthly peak cannabis use, it could be inferred that a more
pronounced binge use of marijuana has an additional detrimental
impact on the level of DA in the striatum. However, DA
impairment was found not to be related to the regular amount of
cannabis consumed per month. A possible explanation for this
effect comes from the research by Bolla et al. [19], who identified
organic drug exposure intensity, instead of duration, as a key
factor in developing drug-related neurocognitive deterioration.
Therefore, it seems plausible to assume that binge use of cannabis
is a better predictor of DA impairment than regular consumption.
Additionally, the moderate negative correlation between EBR and
lifetime cannabis consumption suggests that the degree of
impairment of striatal dopaminergic functioning is related to the
total amount of cannabis consumed during lifetime. Possibly, use
of higher doses of cannabis, both in the short- and long-term, has a
more detrimental enduring effect on GABA and glutamate
inhibition of DA in striatum, as compared to the impact of using
smaller doses for a longer period of time.
As for limitations of the present study, one is the lack of
additional verification of participants’ compliance with the no-
consumption instructions. Subjects’ urinary or plasma levels of
THC metabolites (THC-COOH) were not examined to confirm
cannabis use status. Another limitation is the correlative nature of
the study, which does not preclude causal contributions from
possible self-selection factors, such as a predisposition for low
striatal DA production that seduces people to use cannabis. It may
also be suspected that significantly more nicotine smokers in the
chronic cannabis condition might have contributed to the
difference in the observed EBR between groups. However, not
only did the critical effect survive the input of nicotine use as
covariate but research also indicates that the long-term effect of
nicotine on DA is facilitatory rather than inhibitory [20]. This
suggests that, in anything, the observed reduction in EBR provides
a rather conservative estimate of the association between cannabis
use and striatal DA levels.
Concluding, the results of the present study point to less efficient
striatal dopaminergic functioning in chronic cannabis users. This
finding seems crucial in understanding the suspected psychotic
effects of long-term cannabis use and throws some doubts on the
claim that cannabis-induced psychosis results from the combina-
tion of increased striatal and reduced prefrontal DA levels [8].
Additionally, the fact that cannabis has an indirect effect on DA
implies caution in predictions of DA-related disorders due to
chronic cannabis use. As a result of dopaminergic neurons not
being impaired by cannabinoids, long-term consequences of
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directly damaging dopaminergic cells, like cocaine (for a
discussion, see [5]). More research is required in order to identify
the neurophysiological and cognitive effects of continuous
marijuana use, which are likely to be more subtle than in the
case of other recreational drugs.
Materials and Methods
Participants
Fifty-three healthy adults served as participants, 28 chronic
cannabis users and 25 non-user controls. Participants received
either course credit or financial reward. The sample was obtained
from the city of Leiden using local advertisement, posts on
community bulletin boards, and leaflets distributed in Leiden
‘‘coffee shops’’ (in which Dutch law permits selling/serving soft
drugs to customers). Subjects were informed that they will
participate in a study on the cognitive and neural effects of
cannabis.
Following Colzato and Hommel [21], the inclusion criterion for
cannabis users was a weekly consumption of at least 4 joints for a
minimum of 2 years. The exclusion criteria were: (1) current or
previous regular use of other drugs except for cannabis (regular use
defined as having used a drug more than 3 times in a lifetime), (2)
abuse of alcohol (more than 14 units per week), (3) history or
presence of an Axis 1 psychiatric disorder (DSM-IV; assessed with
the use of the Mini International Neuropsychiatric Interview;
M.I.N.I. [22]), (4) clinically significant medical disease, and (5) use
of psychotropic medication. Non-user controls were required to
meet the same criteria, with the exception that they could not
report current or previous cannabis use. Additionally, participants
were not permitted to consume caffeine, chocolate, or alcohol 12
hours before the experimental session, or to use nicotine 2 hours
before the study. It was also not allowed to use cannabis on the day
Figure 1. Years of cannabis exposure as a function of spontaneous eye blink rate per minute.
doi:10.1371/journal.pone.0026662.g001
Figure 2. Peak monthly cannabis consumption (in joints) as a function of spontaneous eye blink rate per minute.
doi:10.1371/journal.pone.0026662.g002
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in order to minimize the impact of possible withdrawal effects of
addicted chronic users. Within the study sample, two participants
were rescheduled for another day due to non-compliance with the
consumption avoidance requirements. Three individuals were
excluded from the group of chronic users because of meeting the
criteria for a psychiatric disorder.
Both groups were matched for age, gender, race (92%
Caucasian, 8% Turkish), and IQ (measured by Raven’s Standard
Progressive Matrices; SPM [23]). The demographic and cannabis
use statistics are presented in Tables 1 and 2, respectively.
Additionally, in Table 1 the results of t-tests are presented to
provide a comparison of demographic group characteristics.
Written informed consent was acquired from all participants after
they had been explained the nature of the study. The protocol and
compensation for participants were approved by the institutional
review board (Leiden University, Institute for Psychological
Research).
Procedure and Design
Spontaneous EBR was recorded using a BioSemi ActiveTwo
system (BioSemi Inc., Amsterdam, the Netherlands). The recording
took place with two horizontal (one left, one right) and two vertical
(one upper, one lower of right eye) Ag-AgCl electrodes. A vertical
electrooculogram (EOG), which records the voltage difference
between two electrodes placed above and below the left eye, was
used to detect eye blinks. A horizontal EOG, which records the
voltage difference between electrodes placed lateral to the external
canthi, was used to measure horizontal eye movements in order to
provide an online preventionof movement artifacts in the data. The
EOGsignals were digitizedat 512 Hz.Data analysis was performed
using Brain Vision Analyzer (Brain Products
TM GmbH, Munich,
Germany; http://www.brainproducts.com/products/analyzer/
index_analyzer.html) with a high-pass filter of 1 Hz applied offline.
Eye blinks were semi-automatically detected using the built-in
Gratton and Coles [24] algorithm. Recordings did not take place
after 5 p.m. due to spontaneous EBR being stable during daytime,
but increasing in the evening (around 8:30 p.m. [25]). Participants
were comfortably sitting in front of a blank poster with a cross in the
center, located about 1 m from the subject. Participants were alone
in the room and asked to look at the cross in a relaxed state. The
recording lasted 6 minutes. Individual EBR was calculated by
dividing the total number of eye blinks during the 6-min
measurement interval by six.
Figure 3. Lifetime cannabis consumption (in joints) as a function of spontaneous eye blink rate per minute.
doi:10.1371/journal.pone.0026662.g003
Table 1. Demographic data.
Non-user
controls
Chronic
cannabis users Significance level
N (M:F) 25 (13:12) 25 (19:6) n.s.
Age (years) 21.7 (3.8) 23.9 (4.4) n.s.
Race 23 C : 2 T 23 C : 2 T n.s.
Raven IQ 124.4 (5.6) 124.2 (7.6) n.s.
Alcohol use 3.1 (2.4) 3.9 (2.8) n.s.
Nicotine use 4 S : 21 NS 21 S : 4 NS **
Standard deviation in parentheses; n.s.: non-significant difference; Race: C –
Caucasian, T – Turkish; Raven IQ: measured by Raven’s Standard Progressive
Matrices; Alcohol use: consumption of units per week; Nicotine use: S – smoker,
NS – non-smoker.
**p,.01.
doi:10.1371/journal.pone.0026662.t001
Table 2. Self-reported cannabis use.
Sample Mean (SD)
Years of exposure 5.4 (4.4)
Age of onset 18.4 (2.9)
Monthly regular use 62.5 (45.7)
Peak use in a month 131.8 (81.6)
Lifetime consumption 4895 (7409.4)
Standard deviation in parentheses; Monthly regular, monthly peak cannabis use
and lifetime consumption: consumption of joints.
doi:10.1371/journal.pone.0026662.t002
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